1. Home
  2. MCO vs MRNA Comparison

MCO vs MRNA Comparison

Compare MCO & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moody's Corporation

MCO

Moody's Corporation

N/A

Current Price

$470.14

Market Cap

83.4B

Sector

Finance

ML Signal

N/A

Logo Moderna Inc.

MRNA

Moderna Inc.

N/A

Current Price

$196.25

Market Cap

91.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MCO
MRNA
Founded
1900
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.4B
91.2B
IPO Year
1998
2018

Fundamental Metrics

Financial Performance
Metric
MCO
MRNA
Price
$470.14
$196.25
Analyst Decision
Buy
Hold
Analyst Count
24
23
Target Price
★ $553.67
$164.53
AVG Volume (30 Days)
765.2K
★ 11.3M
Earning Date
10-21-2026
11-06-2026
Dividend Yield
★ 0.87%
N/A
EPS Growth
21.40
★ 21.77
EPS
★ 12.98
N/A
Revenue
$4,204,100,000.00
★ $19,263,000,000.00
Revenue This Year
$6.50
$24.09
Revenue Next Year
$6.70
$11.33
P/E Ratio
$36.35
★ N/A
Revenue Growth
N/A
★ 4.29
52 Week Low
$402.28
$23.55
52 Week High
$546.88
$280.80

Technical Indicators

Market Signals
Indicator
MCO
MRNA
Relative Strength Index (RSI) 38.39 41.43
Support Level $460.33 $181.02
Resistance Level $476.73 $254.48
Average True Range (ATR) 12.25 18.33
MACD -5.50 -7.45
Stochastic Oscillator 3.58 5.92

Price Performance

Historical Comparison
MCO
MRNA

About MCO Moody's Corporation

Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and often (depending on bond issuance levels) a majority of the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: